Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

NCT07924384 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07924384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas
Lead sponsor
Institut Curie
Phase
Observational
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2034
Enrollment
150 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

non-rhabdomyosarcoma soft tissue sarcomas (nrsts)

Arms

As registered; 1 arm.

  • NRSTS group Intervention

    Single arm for all patients. Tumor samples will be taken for histological and molecular profiling, at baseline (FFPE for routine care or tissue sample from surgery. Blood samples will be taken at baseline and every 3- months up to end of study post surgery.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Histopathological profiling of NRSTS tumors Baseline

    Histopathological description of NRSTS tumors based on analysis of tumor tissue in paraffin. Results will be reported as the number and percentage of tumors classified into each histological subtype.

  • Molecular profiling of NRSTS tumors Baseline

    Molecular profiling of NRSTS tumors combining DNA and RNA profiling, DNA methylation analysis, and clustering. Results will be reported as the number and percentage of tumors presenting identified molecular alterations.

Lead sponsor's other trials

Institut Curie, most recent start first.

Similar trials

Same condition (Neoplasms) and phase, most recent start first.